SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Federal reclassification of cannabis and the elimination of the 280E tax barrier are driving significant attention to Weedcoin, as the community positions it as a key beneficiary of these policy changes on Solana. Enthusiasts are rallying around its 

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending following news of a strategic manufacturing partnership set to scale production of its drug screening reader for anticipated U.S. market entry. The community is actively discussing the stock's massive volume and micro-float, fueling excitement for potential short-squeeze-like parabolic gains. However, a recent private placement with lower-priced warrants has sparked debate among traders, creating a highly volatile environment with divided opinions on its immediate future.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high December and fourth-quarter 2025 vehicle deliveries, meeting the high end of its guidance and nearing one million cumulative vehicles overall. This strong performance, coupled with China's extended EV purchase tax benefits favoring battery-swapping models, has ignited community discussions about potential Q4 profitability and a bright 2026 outlook for the multi-brand EV maker. Many investors are optimistic, comparing NIO's sales favorably against peers and anticipating significant upside despite recent price volatility.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is seeing significant community discussion driven by the departure of its CFO, which has sparked diverse speculation about a potential acquisition, alongside a new expanded access agreement for its rare disease treatment, MIPLYFFA, to broaden global reach. Simultaneously, investors are closely watching the ongoing legal proceedings with Commave, with varying interpretations of recent court developments influencing sentiment around the future of its KP1077 asset.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF is generating significant buzz as investors grapple with its perceived disconnection from the underlying asset. Intense community discussions center on the impact of distributions and the inherent decay of this leveraged product, leading to a polarized debate over its immediate trajectory and risk profile.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending after definitively agreeing to sell Bressner Technology for $22.4M, a strategic move the community views as a profitable pivot to focus on high-growth AI and edge computing. This substantial cash infusion and sharpened corporate focus are fueling strong anticipation for impending large military contracts, particularly a potential $200M situational awareness system. Investors are actively discussing the company's low float and undervalued status, anticipating significant upside as the AI and defense narrative gains wider recognition.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending amid recent regulatory approvals for a key acquisition and an analyst firm initiating coverage with an "Overweight" rating. While some investors voice frustration over past delays in commercial revenue and management communication, a significant portion of the community maintains strong conviction in the long-term potential of its specialized isotope technology for critical sectors including advanced energy, medical applications, and next-generation computing. The conversation highlights a divide between those concerned about execution timelines and those focused on strategic asset accumulation and the company's unique market position.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending amid intense community debate surrounding mixed interim Phase 2 data for its cystic fibrosis therapy, ARCT-032, where positive mucus plug reduction signals are being weighed against limited lung function improvement. Concurrently, investors are closely following a high-stakes trade secret lawsuit against AbbVie, which many believe could lead to a significant settlement or buyout, fueling conversations about the stock's perceived undervaluation and potential for a substantial short squeeze.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending sharply higher after competitor Corcept Therapeutics ($CORT) received a Complete Response Letter from the FDA for its Cushing's syndrome drug, relacorilant. This news is a significant catalyst, eliminating a potential rival and providing a clearer path for Xeris's approved treatment, Recorlev, to capture substantial market share. The community is buzzing with optimism, viewing this as a massive tailwind that solidifies Recorlev's market position and highlights XERS's undervaluation, despite some expressing disappointment that the stock isn't gaining even more aggressively given the competitor's significant market cap loss.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending due to its recent partnership with Google Cloud for the Agentic Interop Summit, signaling increased recognition and strategic positioning within the AI ecosystem. The community is also reacting to Ocean Protocol's departure from the ASI Alliance, which has led to a significant FET token burn, viewed by many as a deflationary catalyst. Despite past volatility, investors are actively discussing Fetch.ai's potential for real-world AI agent adoption and its perceived undervaluation within the broader AI crypto sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iBio, Inc. (IBIO) Reports Q1 Loss

iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates

Keros Therapeutics (KROS) delivered earnings and revenue surprises of +83.78% and +86.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of +14.71% and +1.49%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Despite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock

Bionano Genomics (BNGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Bionano Genomics (BNGO) Is Attractively Priced Despite Fast-paced Momentum

Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Bionano Genomics triggered&nbsp;heavy retail chatter on Wednesday after the company provided a full-year 2025 revenue forecast in the range of $26 million to $30 million, falling short of the consensus estimate of $30.33 million.The company's second-quarter (Q2) revenue projection fell between $6.3 million and $6.8 million, while analysts expected $7.01 million.Bionano disclosed $6.5 million in revenue for Q1 2025, which surpassed the consensus figure of $6.25 million.&nbsp;The gross margin percentage increased to 46% compared to 32% from the previous year.&nbsp;GAAP operating expenses plunged by 66% to $11.4 million, while non-GAAP costs reduced by 65% to $8.5 million because of downsizing and restructuring product development efforts.Bionano shares closed 5.3% lower at $3.74 on Tuesday but rebounded 20.3% to $4.50 in after-hours trading.CEO Erik Holmlin noted that the March quarter represented the first period for executing their new strategy, which targets routine users of OGM systems and VIA software.&nbsp;The company reported stable utilization rates and increased consumables sales to routine users, which led to an extended cash runway until the first quarter of 2026.Bionano's Q1 sales of nanochannel array flowcells reached 6,994 units, representing a 15% decrease from the previous year, although existing customer sales expanded by 1% when accounting for new account volumes.&nbsp;The company added nine OGM systems to its network in the quarter, which increased its total system count to 379 from 347 at the same time last year.Bionano confirmed its plans to deploy between 15 and 20 new OGM systems in 2025.On Stocktwits, retail sentiment was ‘extremely bearish’ amid a&nbsp;6,300% surge in 24-hour message volume.One user warned of a potential 35% drop in the stock, while another described the company as obsolete and predicted a decline toward zero.<stembedurl>https://stocktwits.com/Jewkee/message/614685155</stembedurl><stembedurl>https://stocktwits.com/v92/message/614672774</stembedurl>The stock has declined 75.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bionano Genomics (NASDAQ: BNGO) logo seen displayed on a smartphone with an Artificial intelligence (AI) chip and symbol in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Bionano Genomics Retail Mood Turns ‘Extremely Bearish’ Amid Revenue Guidance Shortfall

Despite a 46% gross margin improvement and significant cost cuts, the stock fell over 5% on Wednesday before jumping 20% in after-hours trading

Equity

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Current Price	$1.53
Prev Close	$1.50
Open	$1.50
Dividend Yield	0.00%
50-Day Moving Average	$1.66
Beta	1.73
Avg. Volume	315,224.89
PE Ratio	-0.10

52-Week High	$22.80
52-Week Low	$1.45
Market Capitalization	$15.26M
EPS (Annual)	-$88.13
Price to Book	0.30
Revenue Per Employee	$307,760.00
Enterprise Value/EBITDA	N/A

BNGO
Bionano Genomics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BNGO News

BNGOBionano Genomics Inc